Cross-reactivity of urine opiates screening assays with dextromethorphan

IF 2.9 3区医学 Q2 MEDICAL LABORATORY TECHNOLOGY

Clinica Chimica Acta Pub Date : 2025-05-20 DOI:10.1016/j.cca.2025.120378

Kelsey Marshall , Katharine Van Patten , Jesse C. Seegmiller , Ian L Gunsolus

引用次数: 0

Abstract

We present a case of high-dose dextromethorphan ingestion with associated rapid urine drug screening and confirmatory testing demonstrating an apparent false-positive opiates screen. Further testing was performed using alternative screening assays and analysis of drug-free matrices spiked with various concentrations of dextromethorphan and its metabolite, dextrorphan. Results demonstrate a subset of urine opiates screening assays may be susceptible to dextromethorphan cross-reactivity at high concentrations.

查看原文本刊更多论文

尿阿片类药物筛选试验与右美沙芬的交叉反应性

我们提出了一个病例高剂量右美沙芬摄入与相关的快速尿药物筛选和确证性测试显示明显的假阳性阿片类药物筛选。进一步的测试使用替代筛选试验和无药物基质分析，添加不同浓度的右美沙芬及其代谢物右美沙芬。结果表明，尿阿片类药物筛选试验的一个子集可能对高浓度右美沙芬的交叉反应敏感。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Chimica Acta 医学-医学实验技术

CiteScore

10.10

自引率

2.00%

发文量

1268

审稿时长

23 days

期刊介绍： The Official Journal of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Clinica Chimica Acta is a high-quality journal which publishes original Research Communications in the field of clinical chemistry and laboratory medicine, defined as the diagnostic application of chemistry, biochemistry, immunochemistry, biochemical aspects of hematology, toxicology, and molecular biology to the study of human disease in body fluids and cells. The objective of the journal is to publish novel information leading to a better understanding of biological mechanisms of human diseases, their prevention, diagnosis, and patient management. Reports of an applied clinical character are also welcome. Papers concerned with normal metabolic processes or with constituents of normal cells or body fluids, such as reports of experimental or clinical studies in animals, are only considered when they are clearly and directly relevant to human disease. Evaluation of commercial products have a low priority for publication, unless they are novel or represent a technological breakthrough. Studies dealing with effects of drugs and natural products and studies dealing with the redox status in various diseases are not within the journal''s scope. Development and evaluation of novel analytical methodologies where applicable to diagnostic clinical chemistry and laboratory medicine, including point-of-care testing, and topics on laboratory management and informatics will also be considered. Studies focused on emerging diagnostic technologies and (big) data analysis procedures including digitalization, mobile Health, and artificial Intelligence applied to Laboratory Medicine are also of interest.